WO2003082834A3 - Morpholine derivatives and intermediates therefor - Google Patents

Morpholine derivatives and intermediates therefor Download PDF

Info

Publication number
WO2003082834A3
WO2003082834A3 PCT/EP2003/003338 EP0303338W WO03082834A3 WO 2003082834 A3 WO2003082834 A3 WO 2003082834A3 EP 0303338 W EP0303338 W EP 0303338W WO 03082834 A3 WO03082834 A3 WO 03082834A3
Authority
WO
WIPO (PCT)
Prior art keywords
morpholine derivatives
intermediates therefor
amino
methyl
intermediates
Prior art date
Application number
PCT/EP2003/003338
Other languages
French (fr)
Other versions
WO2003082834A2 (en
Inventor
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Original Assignee
Glaxo Group Ltd
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Rachael Ann Ancliff, Caroline Mary Cook, Colin David Eldred, Paul Martin Gore, Lee Andrew Harrison, Martin Alistair Hayes, Simon Teanby Hodgson, Duncan Bruce Judd, Suzanne Elaine Keeling, Xiao Qing Lewell, Gail Mills, Graeme Michael Robertson, Stephen Swanson, Andrew John Walker, Mark Wilkinson filed Critical Glaxo Group Ltd
Priority to JP2003580302A priority Critical patent/JP2006504626A/en
Priority to EP03745295A priority patent/EP1490345A2/en
Priority to AU2003226758A priority patent/AU2003226758A1/en
Publication of WO2003082834A2 publication Critical patent/WO2003082834A2/en
Publication of WO2003082834A3 publication Critical patent/WO2003082834A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compound of formula (I); which is;3-({[({[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)carbonyl]--amino}methyl)-N-ethylbenzamide;and salts and solvates thereof, a process for its preparation, pharmaceutical formulations containing it and its use in therapy.
PCT/EP2003/003338 2002-03-28 2003-03-27 Morpholine derivatives and intermediates therefor WO2003082834A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003580302A JP2006504626A (en) 2002-03-28 2003-03-27 Morpholine derivatives and intermediates thereof
EP03745295A EP1490345A2 (en) 2002-03-28 2003-03-27 Novel compound
AU2003226758A AU2003226758A1 (en) 2002-03-28 2003-03-27 Morpholine derivatives and intermediates therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207447.4 2002-03-28
GBGB0207447.4A GB0207447D0 (en) 2002-03-28 2002-03-28 Novel compounds

Publications (2)

Publication Number Publication Date
WO2003082834A2 WO2003082834A2 (en) 2003-10-09
WO2003082834A3 true WO2003082834A3 (en) 2004-03-25

Family

ID=9933997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003338 WO2003082834A2 (en) 2002-03-28 2003-03-27 Morpholine derivatives and intermediates therefor

Country Status (7)

Country Link
EP (1) EP1490345A2 (en)
JP (1) JP2006504626A (en)
AR (1) AR039176A1 (en)
AU (1) AU2003226758A1 (en)
GB (1) GB0207447D0 (en)
TW (1) TW200401771A (en)
WO (1) WO2003082834A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243959A1 (en) * 1986-04-30 1987-11-04 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
WO1995031431A1 (en) * 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel diaminomethylidene derivative
WO1995031442A1 (en) * 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel pyrimidine derivative
WO1998056771A2 (en) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO2002026723A1 (en) * 2000-09-29 2002-04-04 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243959A1 (en) * 1986-04-30 1987-11-04 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
WO1995031431A1 (en) * 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel diaminomethylidene derivative
WO1995031442A1 (en) * 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel pyrimidine derivative
WO1998056771A2 (en) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO2002026723A1 (en) * 2000-09-29 2002-04-04 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARTORI E ET AL: "SYNTHESIS AND ACTIVITIES OF NET ARYLSULFONAMIDO THROMBOXANE A2 RECEPTOR ANTAGONISTS", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 28, no. 7/8, 1993, pages 625 - 632, XP000396678, ISSN: 0223-5234 *

Also Published As

Publication number Publication date
JP2006504626A (en) 2006-02-09
TW200401771A (en) 2004-02-01
AR039176A1 (en) 2005-02-09
AU2003226758A1 (en) 2003-10-13
GB0207447D0 (en) 2002-05-08
EP1490345A2 (en) 2004-12-29
WO2003082834A2 (en) 2003-10-09
AU2003226758A8 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
NZ502702A (en) Amide derivatives for the treatment of diseases mediated by TNF, IL-1, IL-6 or IL-8
WO2004016578A3 (en) Arylethanolamine beta2-adrenoreceptor agonist compounds
NZ514234A (en) N-cyanomethylamides as protease inhibitors
DK1682503T3 (en) Derivatives of N- (phenyl1 / alkylpiperdin-2-yl) methyl) benzamide, preparation and use thereof in therapy
WO2002010154A3 (en) Substituted heterocyclic amides
HK1080856A1 (en) Compounds having selective inhibiting effect at gsk3
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
AU2055500A (en) Aromatic amides
FI950309A0 (en) proline amide derivative
ATE326453T1 (en) ANTITHRBOTIC AMIDES
MXPA04004548A (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors.
FR2861070B1 (en) DERIVATIVES OF N- [PHENYL (PYRROLIDIN-2-YL) METHYL] BENZAMIDE AND N - [(AZEPAN-2-YL) PHENYLMETHYL] BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC USE
HUP0302553A2 (en) Salts of a isothiazole-4-carboxamide and process for their preparation and use for the preparation of anti-hyperproliferation agents
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
DE60035429D1 (en) USE OF SULFODE HYDROABETIC ACIDS FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
MXPA04005484A (en) Method for preparing echinocandin derivatives.
AR039177A1 (en) MORFOLINA DERIVATIVES, CCR3 ANTAGONISTS.
WO2003082834A3 (en) Morpholine derivatives and intermediates therefor
ZA959311B (en) 5-(aryloxymethyl)oxazolines a process for the preparation thereof and pharmaceutical compositions containing them
ZA200300218B (en) Novel N-(2-phenyl-3-aminopropyl)naphtamides.
SE9900190D0 (en) New compounds
BR0214780A (en) Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
HK1073112A1 (en) 3-(Cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003580302

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003745295

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003745295

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003745295

Country of ref document: EP